Finally, our group has shown that inhibiting the TGFβ pathway at multiple levels using inhibitors of the TGFβ ligands, the TGFβ receptors, and TGFβ transducers (such as SMAD3) improves hematopoiesis in FA preclinical models. Here, TGFB1 is linked to Friedreich ataxia.